SERTAD2 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma, ZNF185 and SERTAD2 are tumor immune targets, providing new ideas for treatment of tumor immune invasion (Chen et al., 2021; Zhang et al., 2022).